BRIEF-Bristol Myers Posts Q1 Adj EPS $-4.40

Reuters04-25

April 25 (Reuters) - Bristol-Myers Squibb Co :

* Q1 EPS $-5.89

* Q1 OPDIVO REVENUE $2.08 BILLION, DOWN 6%

* Q1 ADJUSTED EPS $-4.40 VERSUS LSEG IBES ESTIMATE $-4.44

* Q1 ELIQUIS REVENUE $3.72 BILLION, UP 9%

* Q1 REVENUE $11.87 BILLION VERSUS LSEG IBES ESTIMATE $11.46 BILLION

* Q1 RESULTS INCLUDE ONE-TIME NET IMPACT OF ACQUIRED IPRD & LICENSING INCOME OF $-6.30 FROM RECENT ACQUISITIONS

* SEES DILUTION IMPACT TO FY ADJUSTED EPS OF $0.13 FROM RAYZEBIO DEAL, $0.30 FROM KARUNA DEAL

* Q1 RESULTS INCLUDE $12.1 BILLION ONE-TIME CHARGE FOR ACQUISITION OF KARUNA THERAPEUTICS

* EXECUTING PRODUCTIVITY INITIATIVE TO DELIVER ABOUT $1.5 BILLION COST SAVINGS BY 2025-END

* OUTLOOK FY ADJUSTED EPS $0.40 TO $0.70 VERSUS LSEG IBES ESTIMATE $0.65

* FY REVENUE FORECAST UNCHANGED; LSEG IBES ESTIMATE $45.91 BILLION

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2430403078?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-25 18:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2430403078","market":"us","top_or_hot":-1,"title":"BRIEF-Bristol Myers Posts Q1 Adj EPS $-4.40","media":"Reuters","content":"<html><body><p>April 25 (Reuters) - Bristol-Myers Squibb Co   :</p><p>   * Q1 EPS $-5.89</p><p>   * Q1 OPDIVO REVENUE $2.08 BILLION, DOWN 6%</p><p>   * Q1 ADJUSTED EPS $-4.40 VERSUS LSEG IBES ESTIMATE $-4.44</p><p>   * Q1 ELIQUIS REVENUE $3.72 BILLION, UP 9%</p><p>   * Q1 REVENUE $11.87 BILLION VERSUS LSEG IBES ESTIMATE $11.46 BILLION</p><p>   * Q1 RESULTS INCLUDE ONE-TIME NET IMPACT OF ACQUIRED IPRD &amp; LICENSING INCOME OF $-6.30 FROM RECENT ACQUISITIONS</p><p>   * SEES DILUTION IMPACT TO FY ADJUSTED EPS OF $0.13 FROM RAYZEBIO DEAL, $0.30 FROM KARUNA DEAL</p><p>   * Q1 RESULTS INCLUDE $12.1 BILLION ONE-TIME CHARGE FOR ACQUISITION OF KARUNA THERAPEUTICS</p><p>   * EXECUTING PRODUCTIVITY INITIATIVE TO DELIVER ABOUT $1.5 BILLION COST SAVINGS BY 2025-END</p><p>   * OUTLOOK FY ADJUSTED EPS $0.40 TO $0.70 VERSUS LSEG IBES ESTIMATE $0.65</p><p>   * FY REVENUE FORECAST UNCHANGED; LSEG IBES ESTIMATE $45.91 BILLION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Bristol Myers Posts Q1 Adj EPS $-4.40</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Bristol Myers Posts Q1 Adj EPS $-4.40\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-25 18:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 25 (Reuters) - Bristol-Myers Squibb Co   :   * Q1 EPS $-5.89   * Q1 OPDIVO REVENUE $2.08 BILLION, DOWN 6%   * Q1 ADJUSTED EPS $-4.40 VERSUS LSEG IBES ESTIMATE $-4.44   * Q1 ELIQUIS REVENUE $3.72...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRTX","symbol_name":"Mirati Therapeutics Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2430403078","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2430403078","pubTimestamp":1714042746,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 25  - Bristol-Myers Squibb Co   :   * Q1 EPS $-5.89   * Q1 OPDIVO REVENUE $2.08 BILLION, DOWN 6%   * Q1 ADJUSTED EPS $-4.40 VERSUS LSEG IBES ESTIMATE $-4.44   * Q1 ELIQUIS REVENUE $3.72 BILLION, UP 9%   * Q1 REVENUE $11.87 BILLION VERSUS LSEG IBES ESTIMATE $11.46 BILLION   * Q1 RESULTS INCLUDE ONE-TIME NET IMPACT OF ACQUIRED IPRD & LICENSING INCOME OF $-6.30 FROM RECENT ACQUISITIONS   * SEES DILUTION IMPACT TO FY ADJUSTED EPS OF $0.13 FROM RAYZEBIO DEAL, $0.30 FROM KARUNA DEAL   * Q1 RESULTS INCLUDE $12.1 BILLION ONE-TIME CHARGE FOR ACQUISITION OF KARUNA THERAPEUTICS   * EXECUTING PRODUCTIVITY INITIATIVE TO DELIVER ABOUT $1.5 BILLION COST SAVINGS BY 2025-END   * OUTLOOK FY ADJUSTED EPS $0.40 TO $0.70 VERSUS LSEG IBES ESTIMATE $0.65   * FY REVENUE FORECAST UNCHANGED; LSEG IBES ESTIMATE $45.91 BILLIONSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MRTX":"Mirati Therapeutics Inc.","BMY":"施贵宝","KRTX":"Karuna Therapeutics","RYZB":"RayzeBio, Inc.","MYE":"Myers Industries Inc"},"translate_title":"Bristol Myers发布Q1调整每股收益$-4.40","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYE":1,"BMY":0.9,"KRTX":0.9,"MRTX":0.9,"RYZB":0.9},"content_text":"April 25 (Reuters) - Bristol-Myers Squibb Co   :   * Q1 EPS $-5.89   * Q1 OPDIVO REVENUE $2.08 BILLION, DOWN 6%   * Q1 ADJUSTED EPS $-4.40 VERSUS LSEG IBES ESTIMATE $-4.44   * Q1 ELIQUIS REVENUE $3.72 BILLION, UP 9%   * Q1 REVENUE $11.87 BILLION VERSUS LSEG IBES ESTIMATE $11.46 BILLION   * Q1 RESULTS INCLUDE ONE-TIME NET IMPACT OF ACQUIRED IPRD & LICENSING INCOME OF $-6.30 FROM RECENT ACQUISITIONS   * SEES DILUTION IMPACT TO FY ADJUSTED EPS OF $0.13 FROM RAYZEBIO DEAL, $0.30 FROM KARUNA DEAL   * Q1 RESULTS INCLUDE $12.1 BILLION ONE-TIME CHARGE FOR ACQUISITION OF KARUNA THERAPEUTICS   * EXECUTING PRODUCTIVITY INITIATIVE TO DELIVER ABOUT $1.5 BILLION COST SAVINGS BY 2025-END   * OUTLOOK FY ADJUSTED EPS $0.40 TO $0.70 VERSUS LSEG IBES ESTIMATE $0.65   * FY REVENUE FORECAST UNCHANGED; LSEG IBES ESTIMATE $45.91 BILLIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430403078"}